Evaluating noninvasive brain stimulation to treat overactive bladder in individuals with multiple sclerosis: a randomized controlled trial protocol.
Betsy H Salazar, Kristopher A Hoffman, John A Lincoln...
https://pubmed.ncbi.nlm.nih.gov/38273296/Actively Recruiting
Led by The Methodist Hospital Research Institute · Updated on 2026-03-23
29
Participants Needed
1
Research Sites
N/A
Total Duration
Neurogenic overactive bladder NOAB is a common issue in women with multiple sclerosis MS, causing symptoms like frequent urination, urgency, and incontinence during bladder storage. Current treatments often have limited success and side effects. This study explores a new approach that targets brain regions involved in bladder control using repetitive transcranial magnetic stimulation rTMS, aiming to improve symptoms by restoring brain function rather than focusing only on the bladder itself. Participants will receive either active or sham rTMS treatment using the Magstim Rapid2 system, which delivers magnetic stimulation to specific brain regions identified by functional MRI and neural navigation. Treatment involves 10 sessions over two weeks, with daily 40-minute sessions of either low-frequency or high-frequency stimulation at 90% of resting motor threshold. After the initial trial period, participants may opt to join an open-label extension phase to continue receiving treatment. Throughout the study, women with MS will undergo screening, MRI scans, and detailed assessments including bladder diaries and symptom questionnaires before and after treatment. Researchers will monitor brain activity changes with functional MRI and track symptoms using the Neurogenic Bladder Symptom Score and bladder capacity measurements at multiple points up to three months post-treatment. The total participation time spans about 4 to 5 months, including follow-up visits to assess safety and long-term effects.
CONDITIONS
Neuromodulating Cortical Regions Involved in Neurogenic Bladder in MS
R
Rose Khavari, MD
B
Betsy Salazar, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
The Methodist Hospital Research Institute
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Active rTMS (Magstim Rapid2 System) | Sham rTMS (Placebo Comparator) |
|---|---|---|
| What it is | Repetitive transcranial magnetic stimulation (rTMS) applied with the Magstim Rapid2 System, using an active coil to deliver targeted magnetic pulses to specific brain regions involved in lower urinary tract function. | Sham rTMS procedure using an identical-appearing coil that replicates the sound of active rTMS but does not deliver magnetic stimulation to the brain. |
| Role in the study | Participants assigned to receive active rTMS serve as the investigational treatment group. Their outcomes are compared against those receiving sham treatment. | Participants assigned to receive sham rTMS serve as the placebo comparator group, allowing evaluation of the effects of actual magnetic brain stimulation versus no stimulation. |
| Primary use | Investigating whether active rTMS can improve symptoms of neurogenic bladder dysfunction in women with multiple sclerosis. | Serves as a placebo comparison to measure the effects of active brain stimulation, without delivering magnetic pulses. |
| How it is given or performed | Participants receive active rTMS with the Magstim Rapid2 device and the D70 Alpha coil. The brain region is targeted using the StimGuide navigation system for precision. | Participants receive sham rTMS using a coil that looks and sounds like the active device but does not deliver magnetic stimulation to the brain. |
| Evidence status | Evidence for the effectiveness of rTMS in treating neurogenic bladder symptoms in MS is currently limited to early-phase and pilot studies. Results from this study are not yet available. | Sham rTMS provides a control for measuring the effects of active stimulation and has no expected clinical benefit on neurogenic bladder symptoms. |
| Important limitations | The clinical benefit of rTMS for neurogenic bladder in MS is not established and is currently supported mainly by small-scale trials. Larger, well-powered studies are needed to confirm efficacy and long-term impact. | Sham devices are effective controls for excluding placebo effects but do not provide information about current standard-of-care options or alternative therapies outside the trial. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 2 weeks
Participants receive neuronavigated repetitive transcranial magnetic stimulation (rTMS) or sham stimulation to modulate brain regions involved in bladder function.
5 visits per week (in-person) for 2 weeks
Duration - 3 months
Participants are followed to assess clinical symptoms, brain imaging changes, and safety after treatment.
4 visits (1 week, 1 month, and 3 months after treatment plus baseline)
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Betsy H Salazar, Kristopher A Hoffman, John A Lincoln...
https://pubmed.ncbi.nlm.nih.gov/38273296/Rose Khavari, Saba N Elias, Timothy Boone...
https://pubmed.ncbi.nlm.nih.gov/30311665/Zhaoyue Shi, Khue Tran, Christof Karmonik...
https://pubmed.ncbi.nlm.nih.gov/33512570/Rose Khavari, Khue Tran, Santosh A Helekar...
https://pubmed.ncbi.nlm.nih.gov/34694911/Khue Tran, Zhaoyue Shi, Christof Karmonik...
https://pubmed.ncbi.nlm.nih.gov/33757581/Rose Khavari, Christof Karmonik, Michael Shy...
https://pubmed.ncbi.nlm.nih.gov/27664581/Khue Tran, Christof Karmonik, Timothy B Boone...
https://pubmed.ncbi.nlm.nih.gov/32265400/Rose Khavari, Saba N Elias, Rashmi Pande...
https://pubmed.ncbi.nlm.nih.gov/30076906/The Methodist Hospital Research Institute
Lead Sponsor